148 related articles for article (PubMed ID: 22067439)
21. Oxidized-phospholipids in reconstituted high density lipoprotein particles affect structure and function of recombinant paraoxonase 1.
Kar S; Patel MA; Tripathy RK; Bajaj P; Pande AH
Biochim Biophys Acta; 2013 Dec; 1831(12):1714-20. PubMed ID: 23973798
[TBL] [Abstract][Full Text] [Related]
22. Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice.
She ZG; Zheng W; Wei YS; Chen HZ; Wang AB; Li HL; Liu G; Zhang R; Liu JJ; Stallcup WB; Zhou Z; Liu DP; Liang CC
Circ Res; 2009 May; 104(10):1160-8. PubMed ID: 19359600
[TBL] [Abstract][Full Text] [Related]
23. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells.
Mackness B; Hine D; Liu Y; Mastorikou M; Mackness M
Biochem Biophys Res Commun; 2004 Jun; 318(3):680-3. PubMed ID: 15144891
[TBL] [Abstract][Full Text] [Related]
24. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis.
Shih DM; Gu L; Xia YR; Navab M; Li WF; Hama S; Castellani LW; Furlong CE; Costa LG; Fogelman AM; Lusis AJ
Nature; 1998 Jul; 394(6690):284-7. PubMed ID: 9685159
[TBL] [Abstract][Full Text] [Related]
25. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins.
Oda MN; Bielicki JK; Ho TT; Berger T; Rubin EM; Forte TM
Biochem Biophys Res Commun; 2002 Jan; 290(3):921-7. PubMed ID: 11798161
[TBL] [Abstract][Full Text] [Related]
26. Paraoxonase-1 and oxidized lipoprotein lipids. The Cardiovascular Risk in Young Finns Study.
Kresanov P; Vasankari T; Ahotupa M; Kaikkonen J; Hutri-Kähönen N; Juonala M; Kähönen M; Lehtimäki T; Viikari J; Raitakari OT
Atherosclerosis; 2015 Aug; 241(2):502-6. PubMed ID: 26091975
[TBL] [Abstract][Full Text] [Related]
27. The effect of HDL mimetic peptide 4F on PON1.
Vakili L; Hama S; Kim JB; Tien D; Safarpoor S; Ly N; Vakili G; Hough G; Navab M
Adv Exp Med Biol; 2010; 660():167-72. PubMed ID: 20221879
[TBL] [Abstract][Full Text] [Related]
28. Serum oxidized low density lipoprotein, paraoxonase 1 and lipid peroxidation levels during oral glucose tolerance test.
Serin O; Konukoglu D; Firtina S; Mavis O
Horm Metab Res; 2007 Mar; 39(3):207-11. PubMed ID: 17373636
[TBL] [Abstract][Full Text] [Related]
29. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G
Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278
[TBL] [Abstract][Full Text] [Related]
30. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity.
James RW; Deakin SP
Free Radic Biol Med; 2004 Dec; 37(12):1986-94. PubMed ID: 15544917
[TBL] [Abstract][Full Text] [Related]
31. Protective effect of human HDL against Cu(2+)-induced oxidation of astrocytes.
Ferretti G; Bacchetti T; Moroni C; Vignini A; Curatola G
J Trace Elem Med Biol; 2003; 17 Suppl 1():25-30. PubMed ID: 14650625
[TBL] [Abstract][Full Text] [Related]
32. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
Brites FD; Verona J; Schreier LE; Fruchart JC; Castro GR; Wikinski RL
Arch Med Res; 2004; 35(3):235-40. PubMed ID: 15163466
[TBL] [Abstract][Full Text] [Related]
33. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity.
Jaouad L; Milochevitch C; Khalil A
Free Radic Res; 2003 Jan; 37(1):77-83. PubMed ID: 12653220
[TBL] [Abstract][Full Text] [Related]
34. HDL--associated paraoxonase 1 (PON1) and dietary antioxidants attenuate lipoprotein oxidation, macrophage foam cells formation and atherosclerosis development.
Aviram M
Pathophysiol Haemost Thromb; 2006; 35(1-2):146-51. PubMed ID: 16855361
[No Abstract] [Full Text] [Related]
35. Consumption of argan oil may have an antiatherogenic effect by improving paraoxonase activities and antioxidant status: Intervention study in healthy men.
Cherki M; Derouiche A; Drissi A; El Messal M; Bamou Y; Idrissi-Ouadghiri A; Khalil A; Adlouni A
Nutr Metab Cardiovasc Dis; 2005 Oct; 15(5):352-60. PubMed ID: 16216721
[TBL] [Abstract][Full Text] [Related]
36. How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae.
Soran H; Schofield JD; Liu Y; Durrington PN
Curr Opin Lipidol; 2015 Aug; 26(4):247-56. PubMed ID: 26103614
[TBL] [Abstract][Full Text] [Related]
37. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification.
Mackness B; Mackness MI; Arrol S; Turkie W; Durrington PN
FEBS Lett; 1998 Feb; 423(1):57-60. PubMed ID: 9506841
[TBL] [Abstract][Full Text] [Related]
38. Variation in paraoxonase-1 activity and atherosclerosis.
Soran H; Younis NN; Charlton-Menys V; Durrington P
Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
[TBL] [Abstract][Full Text] [Related]
39. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.
Van Lenten BJ; Hama SY; de Beer FC; Stafforini DM; McIntyre TM; Prescott SM; La Du BN; Fogelman AM; Navab M
J Clin Invest; 1995 Dec; 96(6):2758-67. PubMed ID: 8675645
[TBL] [Abstract][Full Text] [Related]
40. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite.
Connelly PW; Draganov D; Maguire GF
Free Radic Biol Med; 2005 Jan; 38(2):164-74. PubMed ID: 15607900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
